Designing Longevity
Skip to main content
Limited EvidencePeptide

Selank

TP-7

Anxiolytic Peptide (tuftsin analog)

Last updated: August 2026
Share:

Evidence Level: Limited Evidence

Mostly animal data or anecdotal reports, theoretical basis

Regulatory Status: Approved as a prescription anxiolytic in the Russian Federation. Not approved in the US or EU. Added to FDA 503A Category 2 in 2023 and removed from Category 2 in September 2024, without being added to the permitted list.

Selank is a synthetic peptide based on tuftsin, a fragment of an immune antibody, with a stabilizing tail added so it survives long enough to work. It is a registered prescription anti-anxiety medication in Russia, taken as a nasal spray. Outside Russia it has never been evaluated in a trial meeting Western regulatory standards.

How It Works

Selank is built from tuftsin, a four-amino-acid fragment that comes from the heavy chain of immunoglobulin G, one of your antibodies. Tuftsin itself has immune-modulating activity but breaks down almost instantly in the body. Russian researchers attached a short stabilizing sequence to the end, producing a peptide that lasts long enough to be useful. That is Selank.

What it appears to do. The mechanism as described in the Russian literature involves several threads:

GABA signaling. Selank appears to affect the expression of GABA-related genes. GABA is your brain's main calming neurotransmitter, and it is the system benzodiazepines act on. The claimed advantage of Selank is producing anxiolytic effects through this system without the sedation, tolerance, and dependence that come with benzodiazepines.

. Selank has been reported to increase , a protein involved in neuron growth and survival, which is the basis for its cognitive and mood claims.

Enkephalin metabolism. It appears to slow the breakdown of enkephalins, your body's own opioid-like peptides involved in mood and pain regulation.

Immune signaling. Because it derives from an antibody fragment, it retains some immune-modulating activity, which is part of why it was originally investigated.

The honest assessment of the evidence. Selank is a registered prescription drug in Russia, which means it cleared that country's regulatory process. But the trials supporting it are predominantly Russian-language, conducted by a limited number of affiliated groups, often small, and frequently without the blinding and placebo controls that Western regulators require. No randomized controlled trial of Selank meeting Western regulatory standards has been published for any indication.

That is not the same as saying Selank does not work. It is saying that if it works, we do not have the kind of evidence that would let us know. Those are genuinely different situations, and most content about Selank collapses them.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Cognitive functionVery Low certainty

Reduces anxiety without sedation or dependence.

Population: Adults with generalized anxiety disorder, as studied in Russian clinical practice

Why this rating

Selank is a registered prescription anxiolytic in Russia, so it satisfied that regulator. The published support is concentrated in Russian-language studies from a small number of affiliated groups, frequently small and often lacking the blinding and placebo controls that Western regulators require. No trial meeting those standards has been published. Anxiety outcomes are also highly placebo-responsive, which makes unblinded evidence particularly weak here.

GRADE downgrade factors applied

  • Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).
  • Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.
  • Publication bias: Suspicion that negative or null results were not published, inflating apparent effect.

Supporting studies

  • Russian clinical studies of Selank in anxietyRandomized Controlled Trial

    Reported anxiolytic efficacy in Russian clinical use, without independent replication under Western trial standards.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Cognitive functionPreclinical certainty

Improves memory, focus, or cognitive performance.

Population: No adequately controlled human population has been studied for this outcome.

Why this rating

The cognitive claims rest on animal work showing increased BDNF and altered neurotransmitter gene expression, plus secondary observations in anxiety studies. We could not identify a controlled human trial of Selank with cognitive performance as a primary outcome. Improving anxiety can improve cognitive performance indirectly, which makes untangling a direct nootropic effect harder, not easier.

Supporting studies

  • Selank effects on BDNF and neurotransmitter gene expressionAnimal Study

    Increased BDNF and altered GABA-related gene expression in animal models.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

  • A registered prescription medication in Russia, meaning it cleared a real regulatory process somewhere
  • Reported anxiolytic effects without the sedation, tolerance, or dependence associated with benzodiazepines
  • Nasal spray administration, so no injection required
  • Reported to increase , a protein involved in neuron growth and survival
  • Decades of clinical use in Russia with no major safety scandal
  • Generally reported as well tolerated, with a mild side effect profile

Risks & Considerations

  • No randomized controlled trial meeting Western regulatory standards has been published for any indication
  • The supporting evidence is concentrated in Russian-language literature from a small number of affiliated research groups
  • Many of the supporting studies lack blinding, placebo controls, or adequate sample sizes
  • Not approved in the US or EU, so US supply is unregulated with no verified purity or dose
  • No published long-term safety data outside the Russian clinical experience
  • Treating clinically significant anxiety with an unverified compound instead of a proven treatment carries real cost
  • Interactions with psychiatric medications are unstudied

Dosing Information

Russian clinical use has established dosing conventions. There is no Western dosing guidance because there has been no Western trial.

  • •Russian clinical use: typically 250 to 300mcg daily, given intranasally, divided across the day
  • •Courses of roughly 10 to 14 days are common in Russian practice
  • •Nasal administration is the standard route, aiming for direct nose-to-brain delivery
  • •Some Western vendors sell injectable preparations, which is not how it is used clinically in Russia
  • •Often stacked with Semax in community protocols, a combination with no trial evidence

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1If you have clinically significant anxiety, treatments with real trial evidence exist and should come first
  • 2The nasal spray is the form with the actual clinical track record. Injectable preparations are a Western improvisation
  • 3Do not combine with psychiatric medication without telling your prescriber. Interactions are unstudied
  • 4Be careful reading Selank sources. A lot of what circulates in English traces back to translated summaries rather than the underlying studies
  • 5Judge it on something objective if you try it. Anxiety is highly responsive to placebo, which is precisely why blinded trials matter here

Key Research

Selank clinical use in generalized anxiety disorder

Russian-language clinical literature

Russian clinical studies report anxiolytic effects comparable to benzodiazepines without sedation or dependence. These studies are generally small, are published in Russian-language journals, and have not been independently replicated under Western trial standards.

Selank effects on gene expression and BDNF

Preclinical and mechanistic studies

Selank altered expression of GABA-related genes and increased BDNF in animal models, and slowed enkephalin degradation.

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has limited human evidence.

Frequently Asked Questions

Is Selank approved anywhere?

Yes, in Russia, where it is a registered prescription anxiolytic sold as an intranasal formulation. It is not approved in the United States or the European Union. The FDA placed it in of the bulk substances list in 2023 and removed it from Category 2 in September 2024, without adding it to the permitted list.

Does Selank actually work for anxiety?

Russian clinical studies report that it does, with effects described as comparable to benzodiazepines but without sedation or dependence. The problem is the quality of that evidence: the studies are largely Russian-language, from a limited number of affiliated groups, often small, and frequently without proper blinding or placebo controls. Anxiety responds strongly to placebo, which makes unblinded evidence especially unreliable here.

Is Selank safer than benzodiazepines?

That is the central claim, and it is mechanistically plausible: Selank appears to influence GABA signaling indirectly through gene expression rather than binding the receptor directly the way benzodiazepines do, which could avoid tolerance and dependence. Decades of Russian clinical use have not produced a major safety scandal. But "no reported problem" and "demonstrated safety" are different standards, and no long-term controlled safety study exists.

What is the difference between Selank and Semax?

Different origins and different emphases. Selank derives from tuftsin, an immune antibody fragment, and is used in Russia for anxiety. Semax derives from ACTH and is used in Russia for stroke recovery and cognitive indications. Both are intranasal, both are Russian-registered, and both share the same core evidence problem: the supporting research has not been replicated to Western standards.

How do you take Selank?

In Russian clinical practice it is an intranasal spray, typically 250 to 300mcg daily divided across the day, in courses of around 10 to 14 days. Nasal administration is used because it allows more direct delivery toward the brain. Some Western vendors sell injectable versions, which does not reflect how the drug is actually used clinically.

Does Selank have side effects?

It is generally reported as well tolerated, with nasal irritation being the most commonly mentioned effect. The honest answer is that side effect data outside Russian clinical experience is essentially nonexistent, and interactions with psychiatric medications have not been studied. If you take anything for mood or anxiety already, tell your prescriber.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Sharper Mind Guide

Compare Selank

Semax vs Selank

Different jobs, and the same evidence problem

Related Peptides

SemaxNeuroprotective Peptide (ACTH fragment analog)
DSIPSleep-Associated Nonapeptide

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated August 2026.

Found this helpful? Share it or save it for later.

Share: